New CAR-T therapy targets Tough-to-Treat myeloma
NCT ID NCT06185751
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new type of CAR-T cell therapy, called WS-CART-CS1, in 25 people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy targets a protein called CS1 found on myeloma cells. The main goals are to check safety and see if the treatment can shrink the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CS1 CAR-T cells (WS-CART-CS1)
What this could lead to
If it works, this could offer a new treatment option for multiple myeloma patients who have run out of effective therapies.
What could go wrong
This is an early Phase 1 trial with only 25 participants, so it is too soon to know if it will be safe or effective. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact